Ruirui Yang

This study shows that resistance to different WRN inhibitors in MSI-H cancers creates orthogonal vulnerabilities, enabling alternating therapy and mutation-tolerant inhibitor design.

PertKGE improves compound-protein interaction prediction using knowledge graph embedding of perturbation transcriptomics, outperforming baselines in cold-start settings and identifying novel therapeutic targets.

This paper introduces a sequence-to-drug paradigm using TransformerCPI2.0 to discover drug-like molecules from protein sequences and validates its effectiveness for three targets.